GSKVX000000048111

GSKVX000000048111 is an investigational supra-seasonal (universal) influenza vaccine candidate developed by GSK in collaboration with the Icahn School of Medicine at Mount Sinai. The vaccine utilizes chimeric hemagglutinin (cHA) technology, which involves constructs that pair a highly conserved HA stalk region (typically from an H1 strain) with exotic HA head domains (such as H5 or H8) to which the human population has little pre-existing immunity. This strategy is designed to redirect the immune response away from the immunodominant but highly variable head region and toward the subdominant but conserved stalk region. By inducing broadly neutralizing antibodies against the HA stalk, GSKVX000000048111 aims to provide protection against a wide range of influenza A subtypes, potentially eliminating the need for annual strain-specific vaccine updates. The candidate is typically formulated with GSK's AS03 adjuvant system and has been evaluated in Phase 1 and Phase 2 clinical trials for safety and immunogenicity.

Other names

GSK supra-seasonal influenza vaccineGSK universal influenza vaccine candidate